Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 166   

Articles published

BMY 64.20 -0.69 (-1.06%)
price chart
Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical ...
NEW YORK & TOKYO--(BUSINESS WIRE)--Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151,“Kyowa Hakko Kirin”) and Bristol-Myers Squibb Company (NYSE:BMY, “Bristol-Myers Squibb”) today announced that the companies have entered into a clinical trial ...
Bristol-Myers Squibb Earnings: Did Opdivo & Elqiuis Sales Could Positively ...
Bristol-Myers Squibb's stock has been on a gradual uptrend, and it is not hard to understand why. In fact, we recently upgraded our own price estimate for BMY to $65 per share.
Bristol-Myers Squibb Receives Breakthrough Designation for HIV Treatment  Wall Street Journal
Bristol-Myers Squibb Co (BMY) Q2 Earnings: What To Expect?  Bidness ETC
Bristol-Myers Squibb Posts Upbeat Q2 Results, Lifts Profit Forecast
Bristol-Myers Squibb Co (NYSE: BMY) reported stronger-than-expected earnings for the second quarter and raised its profit forecast for the full year.
Bristol-Myers Squibb Company (BMY) Leading In Pre-Market Activity
Bristol-Myers' hepatitis C drug sales eclipsed expectations  Business Insider
Large Inflow of Money Witnessed in Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE:BMY) traded with a cut of -1.68 points or -2.55% at $64.3 per share. As per the last available information, the stock aggregated $161.86 million in upticks and $89.72 million in downticks, keeping the net money flow ...
Active Stocks News Alert: General Electric Company (NYSE:GE), Bristol-Myers ...  wsnewspublishers
Bristol-Myers Squibb Company (NYSE:BMY) Had Its Price Objective Upped by ...
Stock Watchlist: Bristol-Myers Squibb Company (NYSE:BMY)
As Bristol-Myers Squibb Company (NYSE:BMY) prepares to next report their earnings on or around 2015-10-23, investors will be keeping a close eye on the reported earnings per share figure and how it compares to the Wall Street analyst consensus ...
Shares of Bristol-Myers Squibb Company (NYSE:BMY) Sees Large Inflow of Net ...  Insider Trading Report
Bristol-Myers Squibb Upgraded at Vetr Inc. (BMY)  Mideast Time
Bristol-Myers Squibb Co. (BMY) Falls 2.55% for July 27
One of the S&P 500's big losers for Monday July 27 was Bristol-Myers Squibb Co. (BMY). The company's stock fell 2.55% to $64.30 on volume of 9.23 million shares.
Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest ...
In separate reports published Thursday, Evercore-ISI's Biotechnology analyst Mark Schoenebaum dissected Eli Lilly and Co (NYSE: LLY) and Bristol-Myers Squibb Co (NYSE: BMY)'s conference call following the release of their quarterly results.
Bristol-Myers' HIV-1 Drug Approved In Europe
Shares of Bristol-Myers Squibb Co (NYSE: BMY) were boosted higher on Thursday after the company announced the European Commission approved its Evotaz for the treatment of HIV-1 in adults.
Bristol-Myers Squibb Co HIV-1 Combo Approved In Europe; A Win For Gilead ...  Bidness ETC
Company Update (NYSE:BMY): European Commission Approves Bristol-Myers Squibb ...  Jutia Group
Did McDonald's, Caterpillar & Amazon Lose Sizzle To Strong Dollar?
Also on the docket to release earnings ahead of Thursday's trading day are Bristol-Myers Squibb Co (NYSE: BMY) and Eli Lilly And Co (NYSE: LLY).
Stock to Follow: Bristol-Myers Squibb Co (NYSE:BMY)
[Business Wire] Bristol-Myers Squibb Co (NYSE:BMY)(TREND ANALYSIS) announced that the European Commission has approved Nivolumab BMS for the treatment of locally advanced or metastatic squamous (SQ) non-small cell lung cancer (NSCLC) after ...
European Commission Approves Nivolumab BMS by Bristol-Myers Squibb for NSCLC  Lung Disease News